Kura Oncology to Participate in Three Investor Conferences in September

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:

Wells Fargo Healthcare Conference
September 8, 2026
3:45 p.m. ET / 12:45 p.m. PT

Cantor Global Healthcare Conference
September 9, 2026
9:10 a.m. ET / 6:10 a.m. PT

Morgan Stanley Global Healthcare Conference
September 16, 2026
7:45 a.m. ET / 4:45 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
[email protected]

You May Also Be Interested In

• SHARC International Systems Inc. Announces Results of 2026 Annual General Meeting
• Venuelocity by Tambourine Elevates Hotel Sales with the Launch of vProposal, a Design-Forward, Integrated Proposal Platform
• Teva Releases Q3 2026 Aide Memoire